(Reuters) -AstraZeneca said on Friday it will invest $2 billion to expand its manufacturing footprint in Maryland as part of its previously announced $50 billion plan to expand manufacturing and research capabilities in the U.S. by 2030.

Global pharmaceutical companies have been ramping up investments in the United States to expand production capacity, following President Donald Trump’s call for the industry to make more medicines domestically instead of importing active ingredients or finished products.

The Anglo-Swedish drugmaker’s $2 billion investment will help expand its biologics manufacturing facility in Frederick and construct a new state-of-the-art facility in Gaithersburg for the development and clinical supply of drugs to be used in trials.

This investment marks the fourth in

See Full Page